胸部放疗的心脏毒性:现有证据与未来方向
该综述汇总了肺癌放疗心脏毒性的现有文献。多种心脏剂量体积参数与心脏毒性和生存相关,但尚无一致约束值;合并心血管危险因素或心脏疾病患者证据不足。文章提出规避与管理策略及未来研究方向。
要点
- 多种心脏剂量体积参数与心脏毒性和生存相关,但无一致约束值。
- 肺癌患者常合并心血管危险因素或心脏病,但相关放疗证据少。
- 需制定策略规避和管理心脏毒性并开展未来研究。
核心结论
- 肺癌放疗心脏毒性已有多种剂量体积参数与毒性及生存相关,但缺乏一致约束值。
研究设计与样本
- 综述汇总肺癌放疗心脏毒性现有文献,并提出策略与研究方向。
主要发现
- 许多不同心脏剂量体积约束与心脏毒性和生存相关,但未发现一致约束。
- 接受肺癌治疗的患者多存在心血管病危险因素或已知心脏合并症,但放疗对心脏影响的证据少。
临床怎么用
- 提出避免和管理心脏毒性的策略,并建议未来研究方向。
局限性
- 合并心血管危险因素或心脏疾病患者中放疗对心脏影响的证据不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The impact of radiotherapy on the heart has become an area of interest in recent years. Many different cardiac dose-volume constraints have been associated with cardiac toxicity and survival; however, no consistent constraint has been found. Many patients undergoing treatment for lung cancer have risk factors for cardiovascular disease or known cardiac comorbidities; however, there is little evidence on the effects of radiotherapy on the heart in these patients. We aim to provide a summary of the existing literature on cardiac toxicity of lung cancer radiotherapy, propose strategies to avoid and manage cardiac toxicity, and suggest avenues for future research.
引用
- Banfill K, Giuliani M, Aznar M, et al. Cardiac Toxicity of Thoracic Radiotherapy: Existing Evidence and Future Directions. J Thorac Oncol. 2020. PMID: 33278607. doi:10.1016/j.jtho.2020.11.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。